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colonography (CTC) for a colorectal cancer screening program in a
working population (aged 40–60 years) from a health care payer’s
perspective in Japan. Methods: A Markov model for colorectal cancer
was constructed to estimate the long-term (10-year, 20-year, and 30-
year) effect of introducing CTC for three different strategies in the
cohort aged 40 years on April 1, 2011. Strategy 1 (the current strategy
in Japan): fecal occult blood test (FOBT) followed by optical colono-
scopy (OC). In this case, 41.8% of those who were FOBT-positive did
not undergo OC (uptake 58.2%). Strategy 2: All FOBT-positive cases
would be offered CTC (uptake 79.1%) followed by OC. Strategy 3: Only
those FOBT-positive cases who were reluctant to undergo OC (41.8%)
would be offered CTC (assumed uptake 50.0%) followed by OC.
Epidemiological data were obtained mainly from statistics published
by the Japanese National Cancer Center. We set quality-adjusted life-
year (QALY) as the primary outcome and colorectal cancer death and
expected life-years as secondary ones. The discount rate for both costsee front matter Copyright & 2014, International S
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13-0033, Japanand outcomes was set at 3%. Results: In the base-case (20-year)
analysis, total cost was increased from Japanese yen (JPY) 65,614
million (strategy 1) to JPY 69,405 million (strategy 2) but was decreased
to JPY 63,878 million (strategy 3). The total QALY increased
from 28,156,046 QALYs (strategy 1) to 28,158,349 (strategy 2) and
28,159,058 QALYs (strategy 3). Therefore, the incremental cost-
effectiveness ratio was JPY 1,646,000 per QALY gained for strategy 2
and strategy 3 was dominant against strategy 1, both of which were
well below the Japanese threshold (JPY 5–6 million per QALY gained).
Conclusion: Adding CTC into the current colorectal cancer screening
program for the working population seems to be a cost-effective
option.
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Epidemiology of Colorectal Cancer in Japan
The 5-year observed survival rates of colorectal cancer in the
member hospitals of the Association of Clinical Cancer Centers
(diagnosed in 2000–2004) were 89% for stage 1, 80% for stage 2,
67% for stage 3, and 15% for stage 4 [1]; therefore, if patients with
stage 4 colorectal cancer were diagnosed at an earlier stage,
deaths from colorectal cancer would be expected to decrease
dramatically. In reality, however, the incidence rate and mortality
of colorectal cancer have been increasing year by year, with
colorectal cancer being the most common and the third most
common cause of cancer-related death in women (30.8/100,000
persons) and men (37.4/100,000 persons), respectively [2,3]. Fur-
thermore, according to the report titled “Estimates of National
Medical Care Expenditures 2010,” colorectal cancer consumed
Japanese yen (JPY) 499.8 billion (US $1 ¼ JPY 85) in 2010, which
was the biggest among all cancers [4].Current Situation and Issues Regarding Colorectal Cancer
Screening in Japan
Current colorectal cancer screening situation
Currently, cancer screening is available for only ﬁve sites: the
stomach, uterine cervix, breasts, lungs, and colon [5,6]. In Japan,
people older than 40 years were recommended to undergo fecal
occult blood test (FOBT) annually, followed by optical colonoscopy
(OC) in those who were FOBT-positive [6]. The Basic Plan to
Promote Cancer Control Program, which was set on the basis of
the Cancer Control Act 2006, aims to raise the uptake in each
cancer screening program to 50% [7]. As a means of early detection
and reducing mortality, colorectal cancer screening by FOBT and
OC, with relevant interventions, has been shown to be effective in
the research project funded by the Ministry of Health, Welfare and
Labor [8]. Improvement in the colorectal cancer screening uptake
may be linked to reducing the incidence rate and mortality.
The uptake of colorectal cancer screening for working age
people, or between 40 and 60 years, in Japan was only 24.8% inociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ﬁgure (50%). Moreover, about 40% of those who were FOBT-
positive did not undergo OC for various reasons [10,11]. Although
some already had colorectal cancer, it would not be detected until
a later stage.
The major reasons why people avoid screening were as
follows: “inconvenient,” “too busy to go to hospital,” and “no
screening institution local to me.” There was also insufﬁcient
understanding about the test, for example, “reluctant to undergo
a painful test” and “unfamiliar with the test” [11].
Future policies and expected issues
In an attempt to increase the uptake of colorectal cancer screen-
ing to 50% among the working age population, the government
has provided FOBT test kits free to those who become 40, 45, 50,
55, or 60 years old since 2011 [11].
Under the assumption that the uptake of the tests was
unaffected by subjects’ colorectal cancer status, if the uptake of
FOBT reached 50% and all subjects who were FOBT-positive
agreed to OC, 64,466 patients with colorectal cancer would be
detected [10]. If the OC screening uptake remained at its current
level (58.2%), however, 26,560 of the 64,466 patients with color-
ectal cancer would not be identiﬁed. The uptake of FOBT and OC
is crucial for both increasing the number of early detected
patients and to reduce the number of colorectal cancer deaths.
Computed tomography colonography
Computed tomography colonography (CTC) is a noninvasive
testing method that diagnoses colorectal cancer by dilating the
colon with gas and taking a three-dimensional image of the colon
using an advanced multislice computed tomography scanner [12].
CTC is less invasive and requires a shorter time for diagnosis than
does conventional OC. Therefore, it is expected to improve the
uptake of colorectal cancer screening. CTC is widely used as a
colorectal cancer screening method in Europe and the United
States. For example, according to the guideline for cancer screen-
ing dispatched by the American Cancer Society in 2008, CTC is
recommended every 5 years for detecting adenomatous polyps
and cancers [13,14]. In Japan, it has been used mainly as a
preoperative diagnostic method for colorectal cancer. The
National Cancer Center of Japan began CTC-based colorectal
cancer screening in November 2010 [12], and this drew attention
to CTC as a screening method. CTC-based colorectal cancer
screening is expected to expand in the future.
Economic Evaluations of CTC for Colorectal Cancer Screening
(Literature Review)
Economic evaluations of CTC in colorectal cancer screening have
already been carried out in the United Kingdom [15,16]. Both
studies chose the same target population (people aged 60–69
years), the same control (current colorectal cancer screening
program in the United Kingdom), and the same perspective (UK
National Health Service). In the United Kingdom, individuals aged
60 to 69 years were offered FOBT every 2 years, followed by OC in
those who were FOBT-positive [15–17].
Lee et al. [15] found that adding CTC to the existing program as
a secondary screening program to triage FOBT-positive patients
was less costly than OC, but increased the number of deaths from
colorectal cancer by 2 people for every 100,000 cases over 10 years.
In contrast, using CTC as a primary screening program every 5
years was more expensive than biennial FOBT screening but
resulted in fewer deaths.
Sweet et al. [16] found that CTC screening offered every 10
years was cost saving compared with the current UK program of
biennial FOBT screening followed by OC. In addition, this strategyyielded greater health beneﬁts (quality-adjusted life-years
[QALYs] and life-years) than did biennial FOBT screening. The
authors suggested, however, that the generalizability of their
results from the UK setting to other countries may not be
appropriate in light of the difference in cost setting, approaches
to using OC in screening, or the age range of the target
population.
In Japan, there has been no economic analysis of CTC for the
colorectal cancer screening program; however, under the situa-
tion that using CTC as a cancer screening method would improve
cost-effectiveness, decision makers needed a study that reveals
an improvement in outcomes and an increase in cost as a result
of introducing CTC as a cancer screening method.Objective
In this study, we aimed to assess the cost-effectiveness of CTC for
the colorectal cancer screening program for the working age
population in Japan. We conducted a cost-effectiveness analysis
of CTC introduction, including its long-term effect, in people aged
40 years on April 1, 2011, from a health care payer’s perspective.
We set QALY as the primary outcome and colorectal cancer death
and expected life-years as secondary ones.Methods
How to Introduce CTC Into the Japanese Colorectal Cancer
Screening Program
We designed the following three colorectal cancer screening
strategies for this study. These strategies are illustrated in
Figure 1. In the explanation below, the numbers in parentheses
indicate the average uptake among people aged 40 to 60 years
based on data from 2010 [9,10]. The uptake for FOBT was 24.8% in
people aged 40 to 60 years and that for OC in FOBT-positive
people aged 40 to 60 years was 58.2%. Because no data were
available for CTC screening, we assumed that half of the patients
who were reluctant to undergo OC would agree to CTC screening
and that all CTC-positive people would agree to OC.
Strategy 1: Current program (without CTC), comparator
Strategy 1 reﬂected the current colorectal cancer screening pro-
gram in Japan. FOBT was performed in those who were eligible for
colorectal cancer screening (uptake 24.8%), and OC was per-
formed in FOBT-positive persons who were willing to undergo
OC (58.2%). CTC was not used.
Strategy 2: Broad implementation of CTC
FOBT was performed in those who are eligible for colorectal
cancer screening (uptake 24.8%). CTC was performed in FOBT-
positive persons who were willing to undergo CTC (79.1%). OC
was performed in all CTC-positive persons (100%). Because 53.2%
of the FOBT-positive persons were thought to be willing to
undergo OC, we assumed that all of them were also willing to
undergo CTC. Among the others (41.8%), we assumed that a half
of them would undergo CTC. Therefore, the overall uptake of CTC
was calculated to be 58.2% þ (0.5  41.8%) ¼ 79.1%.
Strategy 3: Limited implementation of CTC
FOBT was performed in those who were eligible for colorectal
cancer screening (uptake 24.8%). OC was performed in FOBT-
positive persons who were willing to undergo OC (58.2%). In this
strategy, unlike strategy 2, the candidates for CTC were not all
FOBT-positive persons but only those who were FOBT-positive
and also reluctant to undergo OC. We assumed that a half of
Fig. 1 – Flowchart of three CRC screening strategies. CRC, colorectal cancer; CTC, computed tomography colonography; FOBT,
fecal occult blood test; OC, optical colonoscopy. *Finally diagnosed as polyp or CRC and have treatment.
Fig. 2 – Markov model for CRC []. CRC, colorectal cancer.
*Underline means already treated state. †Does not include
the prediagnosed state.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 1 8 2 – 1 8 9184them would undergo CTC. Therefore, CTC was performed in
20.9% [0.5  (100 – 58.2%)] of all FOBT-positive people and OC
was performed in all CTC-positive people (100%).
Analysis
Perspective
Analyses were carried out from a health care payer’s perspective
and included the costs of screening, polypectomy, and cancer
treatment. FOBT costs were excluded from this study because
they would be almost the same among all the three strategies.
Target population
We analyzed a hypothetical cohort consisting of all those who
were 40 years old on April 1, 2011. They were composed of
1,968,500 persons, which was estimated from the number of
people aged 39 and 40 years in the public report about the
population on October 1, 2010 [18].
Model
We constructed a Markov model (Fig. 2) for colorectal cancer, with
reference to previous studies [10–12], and adjusted it using the
available epidemiological data from Japan [1–3,9,10] to estimate
the effectiveness of CTC for colorectal cancer screening of work-
ing age population. One cycle of our Markov-model was set to 1
year, reﬂecting the shortest time period for data collected in our
analysis [15,16,19].
Transition probability
We adjusted the transition probabilities (Table 1) among each
stage on the basis of epidemiological data from Japan [1–3,9,10]
and a previous study [16]. Non–colorectal cancer mortality was
calculated on the basis of colorectal cancer mortality [1] and
mortality table [2].
We set the sensitivity and speciﬁcity of each test to the values
presented in Table 1 on the basis of previous Japanese and foreign
studies [20–27] and discussions with clinical experts.
Previous studies on the sensitivity and speciﬁcity of FOBT [20–
26] have various limitations such as an insufﬁcient sample size, abiased population, or an insufﬁcient description of
the method. After discussion with clinical experts, we used the
Japanese data [20] as provisional values in the base-case
analysis and assumed distributions in the probabilistic sensitiv-
ity analysis.
Although the sensitivity and speciﬁcity of CTC depend largely
on the skills of the physicians, we used the results of a clinical
study [27] after assuming that interphysician variation had been
equalized. Moreover, because there were few physicians in Japan
Table 1 – Valuables in the Markov model (transition probability, cost, and screening characteristics).
Transition probability Cost (JPY) Other variables
Progression (prediagnosed) Test and treatment Uptake rate of test
Normal epithelium to low-risk polyp(s) 0.012 CTC 31,500 FOBT† 0.248
Low-risk polyp(s) to high-risk polyp(s) 0.024 OC 25,000 OC† 0.583
High-risk polyp(s) to Dukes’ A 0.034 Polypectomy (r2 cm in diameter) 78,000 CTC 0.500
Dukes’ A to Dukes’ B 0.583 Polypectomy (Z2 cm in diameter) 98,000 Sensitivity of FOBT
Dukes’ B to Dukes’ C 0.656 Malignant tumor resection (colon) 840,400 Low-risk polyp 0.070
Dukes’ C to Dukes’ D 0.865 Malignant tumor resection (rectum) 1,130,900 High-risk polyp 0.200
Death from colorectal cancer Postoperative chemotherapy 1,016,000 Dukes’ A 0.538
Dukes’ A‡ 0.00545 Chemotherapy (Dukes’ D, annual) 4,259,600 Dukes’ B 0.700
Dukes’ B‡ 0.0282 Follow-up (Dukes’ A and B) 35,600 Dukes’ C and D 0.783
Dukes’ C‡ 0.0532 Follow-up (Dukes’ C and D) 45,000 Sensitivity of CTC
Dukes’ D‡ 0.310 Annual cost by stage Low-risk polyp 0.650
Prediagnosed to postdiagnosed Low-risk and high-risk polyps 78,000 Others 0.900
Dukes’ A presentation 0.065 Dukes’ A (1 y) 98,000 Sensitivity of OC 1.000
Dukes’ B presentation 0.26 Dukes’ A (2–5 y) 35,600 Speciﬁcity
Dukes’ C presentation 0.46 Dukes’ B (1 y) 941,400 FOBT 0.948
Dukes’ D presentation 0.92 Dukes’ B (2–5 y) 35,600 CTC 0.860
Polyp recurrence after polypectomy Dukes’ C (1 y) 1,957,400 OC 1.000
History of low-risk polyp(s) (ﬁrst year) 0.18 Dukes’ C (2–5 y) 45,000
History of low-risk polyp(s) (2 y) 0.05 Dukes’ D (1–5 y) 4,304,600
History of high-risk polyp(s) (ﬁrst year) 0.25
History of high-risk polyp(s) (2 y) 0.06
CRC, colorectal cancer; CTC, computed tomography colonography; FOBT, fecal occult blood test; JPY, Japanese yen; OC, optical colonoscopy.
 Derived from the fee for the cancer screening program at the National Cancer Center in Japan and others were calculated from the guideline
for CRC treatment [30] and health insurance fee schedule [28,29].
† Average values among people aged 40 to 60 y appear in this table. In the actual model, they were varied according to their age [9,10].
‡ Transition probabilities were adjusted by domestic epidemiological data [1–3,9,10] and the other probabilities were referred to a previous
study [16].
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speciﬁcity of CTC were likely to be lower than those published in
this previous report [27]. We assumed distributions in the prob-
abilistic sensitivity analysis to take account of this uncertainty.
Both the sensitivity and speciﬁcity of OC used in the ﬁnal
diagnosis were set to 1.00. If the speciﬁcity was below 1.00, some
people would be false-positively diagnosed and unnecessarily
treated for colorectal cancer. We did not, however, consider this
issue in our model and did not perform any scenario analysis
because there were insufﬁcient Japanese epidemiological data
about false-positive cases and the accuracy of OC itself was not in
the scope of our analysis.
Uptake of each test
As mentioned earlier, we set the uptake of FOBT from the
Comprehensive Survey of Living Conditions 2010 [9] and set the
uptake of OC from the Report on Regional Public Health Services
and Health Promotion Services 2010 [10]. Average uptake of FOBT
and OC among people aged 40 to 60 years is presented in Table 1.
Furthermore, scenario analysis was carried out for the case that
the uptake of FOBT reached the government’s target ﬁgure (50%)
and the case that the uptake of OC was the lowest value (34.1% in
Tokyo) or the highest value (75.0% in Iwate) among 47 prefectures
[10].
Because colorectal cancer screening with CTC was not com-
mon in Japan, there were no national data about the uptake of
CTC; therefore, from discussion with clinical experts, we assumed
that a half of FOBT-positive persons who were reluctant to
undergo OC would agree to CTC screening and that all CTC-
positive people would agree to OC. The uptake of CTC is also
presented in Table 1.Cost
Costs are presented in Table 1 [28–30], all of which are direct
costs. The costs of CTC and OC were based on those for cancer
screening charged at the Japanese National Cancer Center. Treat-
ment costs of colorectal cancer stratiﬁed by Dukes’ classiﬁcation
were calculated from the newest guideline for colorectal cancer
treatment [30]. Under the Japanese health insurance system, in-
patient treatments for colorectal cancer in large hospitals were
charged on the basis of the diagnosis-related group system. Thus,
we used them instead of separately calculating unit price and
resource use [28,29].
Outcome measures
We set QALY as the primary outcome and colorectal cancer death
and expected life-years as secondary ones. Because there were
insufﬁcient Japanese data, we referred the utility scores in a
previous UK study [15,16]. The Basic Plan to Promote Cancer
Control Program aimed to decrease the number of cancer deaths
and to prolong life-years with good health [7]. Thus, we set
colorectal cancer death as well as expected life-year as secondary
outcomes.
Time horizon (duration of analyses)
In the base-case analysis, the time horizon was set to 20 years.
Governmental policy aimed at increasing the uptake of colorectal
cancer screening, especially among those who were of working
age [11]. Therefore, we think that 20 years was sufﬁcient for
capturing whole costs and outcomes accrued during the working
age, or 40 years old to 60 years old. So far, some workers were still
working even after they crossed 60 years, or until they become 65
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time horizon to 10 years, 30 years, and lifetime.
Discount rate
The annual discount rate was set at 3% for both cost and
effectiveness. Scenario analysis was carried out for 0% and 7%
in Shiroiwa et al. [31].
Sensitivity analyses
Scenario analyses were carried out for the following variables for
which we could found the grounds of setting a lower or higher
value: uptake of FOBT (50%) [7], uptake of CTC (25%–75%), uptake
of OC (34.1% and 75.0%) [10], time horizon (10 years, 30 years, and
lifetime), discount rate (0% and 7%) [31], and the cohort aged 50
years with a 10-year time horizon.
Probabilistic sensitivity analyses were also conducted by
adopting distributions for variables incorporated into our model,
as shown in Table 1. We adopted beta distributions for the
parameters for which we could acquire raw data (denominator
and numerator of parameters) and normal distributions for the
parameters for which we could not acquire raw data. Also, we
made estimations of the chemotherapy costs for Dukes’ C and
Dukes’ D patients on the basis of chemotherapy strategies in the
2010 guideline [30] but there were various treatment modalities
and it depends largely on the condition of the patient; therefore,
we assumed the log-normal distribution for the chemotherapy
cost on the basis of estimated costs distribution of each chemo-
therapy strategy, and considered uncertainties related to
chemotherapy cost.Results
Validity of the Model
We constructed a Markov model with reference to previous
studies [15,16,19] and adjusted it for transition probability accord-
ing to Japanese epidemiological data such as the 5-year observed
survival rate, cumulative incidence rate, and cumulative mortal-
ity categorized by Dukes’ classiﬁcation [1–3,9,10]. For example, we
calculated the annual mortality for each Dukes’ classiﬁcation
from Japanese 5-year observed survival rate data. We adjusted
the age-speciﬁc incidence of colorectal cancer using Japanese
data for cumulative incidence rate and mortality. Because thereTable 2 – Result of base-case analysis (unit: 1,968,500 pe
Unit 1 Unit 2 Strategy
1
Strategy
2
Cost (JPY
1,000)
Cost 65,615,000 69,405,000
⊿Cost
Outcome QALY 28,158,046 28,158,349
CRC death 4,693 4,369
ELY 28,711,380 28,713,132
⊿QALY
⊿CRC death
⊿ELY
ICER (JPY
1,000)
per QALY
per CRC death
averted
per LYG
CRC, colorectal cancer; ELY, expected life-year; ICER, incremental cost-
quality-adjusted life-year.
 Strategy 1 was set to control when calculating ICERs.were no data for transition probabilities among the four Dukes’
stages, we referred previous studies [15,16,19] and calibrated
those using current data for the cumulative incidence rate.
Result of the Base-Case Analysis
We calculated the total costs (screening cost þ treatment costs),
the QALYs, the number of colorectal cancer deaths, and the
expected life-years for the hypothetical cohort consisting of all
those who were 40 years old (N ¼ 1,968,500 as of April 1, 2011); the
data are summarized in Table 2.
For the base-case analysis (time horizon 20 years), differences
against strategy 1 were as follows.
Strategy 2 required an additional cost of JPY 3,790,548,000
(from 69,405,291,000 to 65,614,743,000), increased QALYs by 2,303
(from 28,158,349 to 28,156,046), decreased the number of cancer
deaths by 324 people (from 4,693 to 4,369), and increased the
expected life-years by 1,752 person-years (from 28,713,132 to
28,711,380). The incremental cost-effectiveness ratios (ICERs)
were JPY 1,646,000 per QALY gained, JPY 11,683,000 per colorectal
cancer death averted, and JPY 2,164,000 per life-year gained.
Strategy 3 decreased cost by JPY 1,736,198,000 (from
65,614,743,000 to 63,878,545,000), increased QALYs by 3,012 (from
28,159,058 to 28,156,046), decreased the number of cancer deaths
by 434 people (from 4,693 to 4,260), and increased the expected
life-years by 2,323 person-years (from 28,713,702 to 28,711,380).
Strategy 3 was dominant against strategy 1.
Result of scenario analyses
The scenario analyses were carried out for the following four
variables: uptake of FOBT (50%), uptake of CTC (25%–75%), uptake
of OC (34.1% and 75.0%), time horizon (10 years, 30 years, and
lifetime), discount rate (0% and 7%), and the cohort aged 50 years
with a 10-year time horizon.
When the uptake of FOBT reached the government’s target
ﬁgure (50%), the ICERs were JPY 2,795,000 per QALY gained for
strategy 2 and JPY 154,000 per QALY gained for strategy 3,
respectively, which was well below the Japanese threshold (JPY
5–6 million per QALY gained) [31].
When the uptake of CTC decreased from 50% to 25%, the ICER
was JPY 6,175,000 per QALY gained for strategy 2 and strategy 3
was dominant against strategy 1. When the uptake of CTC
improved from 50% to 75%, the ICER was JPY 850,000 per QALY
gained for strategy 2 and strategy 3 was dominant againstrsons aged 40 y on April 1, 2011).
Strategy
3
Strategy 2 vs.
strategy1
Strategy 3 vs.
strategy 1
63,879,000
þ3,790,548 1,736,198
28,159,058
4,260
28,713,702
2,303 3,012
324 434
1,752 2,323
1,646 Dominant
11,683 Dominant
2,164 Dominant
effectiveness ratio; JPY, Japanese yen; LYG, life-year gained; QALY,
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When the uptake of OC decreased to the lowest value among
47 prefectures (34.1% in Tokyo), the ICER was JPY 21,000 per QALY
gained for strategy 2 and strategy 3 was dominant against
strategy 1. When the uptake of OC decreased to the highest value
among 47 prefectures (75.0% in Iwate), the ICER was JPY
11,740,000 per QALY gained for strategy 2 and strategy 3 was
dominant against strategy 1.
When the time horizon was 10 years, ICERs were JPY
19,085,000 per QALY gained for strategy 2 and JPY 5,288,000 per
QALY gained for strategy 3, respectively. When the time horizon
was 30 years, the ICER was JPY 416,000 per QALY gained for
strategy 2 and strategy 3 was dominant against strategy 1. When
the time horizon was lifetime, both strategy 2 and strategy 3 were
dominant against strategy 1.
When the discount rate was 0%, the ICER was JPY 1,217,000 per
QALY gained for strategy 2 and strategy 3 was dominant against
strategy 1. When the discount rate was 7%, the ICER was JPY
2,401,000 per QALY gained for strategy 2 and strategy 3 was
dominant against strategy 1.
When the target population was those who were aged 50 years
on April 1, 2011, and the time horizon was 10 years, ICERs were
JPY 2,685,000 per QALY gained for strategy 2 and JPY 5,468,000 per
QALY gained for strategy 3 against strategy 1.Result of the Probabilistic Sensitivity Analysis
The probabilistic sensitivity analyses showed that color-
ectal cancer screening programs with CTC were likely to be
cost-effective compared with strategy 1 (current program
without CTC).
Figure 3 illustrates that in 95.2% of the simulations, strategy 2
was found to be acceptable at a cost-effective threshold of JPY 5 to
6 million per QALY gained compared with strategy 1. Moreover,
Figure 3 shows that strategy 2 was dominant against strategy 1 in
6.1% of the simulations.Fig. 3 – Scatter plot of probabilistic sensitivity analysis on the cos
JPY, Japanese yen; QALY, quality-adjusted life-year; WTP, willinFigure 4 illustrates that in all simulations, strategy 3 was
found to be acceptable at the cost threshold of JPY 5 to 6 million
per QALY gained compared with strategy 1; moreover, Fig. 4
shows that strategy 3 was dominant against strategy 1 in 74.7% of
the simulations.Discussion
Target Population
As mentioned earlier, since 2011, the Japanese government started
to provide free colorectal cancer screening to those aged 40, 45, 50,
55, or 60 years, aiming to increase the colorectal cancer screening
uptake to the target ﬁgure (50%) among the working age population
[11]. Therefore, to reveal the effect of CTC for the colorectal cancer
screening program among the working age population in Japan, we
set a closed cohort comprising people aged 40 years on April 1,
2011, as our target population and set 20 years (from 40 to 60 years)
as the time horizon in the base-case analysis.
The result of scenario analysis for time horizon showed the
common trend between strategy 2 and strategy 3, that when the
time horizon was longer, the cost-effectiveness of CTC for color-
ectal cancer screening would be improved more. Older persons,
however, were more likely to be diagnosed with colorectal cancer
when they took cancer screening, due to a higher prevalence rate
than in younger people [3]. Therefore, to capture the entire effect
of CTC implementation, we need to expand the time horizon to
lifetime. If we expand the time horizon to lifetime, both strategy 2
and strategy 3 became dominant against strategy 1.
Recurrence of Colorectal Cancer
We did not adapt recurrence and metastasis to this model, which
was due to the lack of data on the recurrence of colorectal cancer
in Japan. Their effect on mortality, however, could implicitly be
reﬂected in the 5-year observed survival rate, while their cost hadt-effectiveness plane for strategy 2 compared with strategy 1.
gness to pay.
Fig. 4 – Scatter plot of probabilistic sensitivity analysis on the cost-effectiveness plane for strategy 3 compared with strategy 1.
JPY, Japanese yen; QALY, quality-adjusted life-year; WTP, willingness to pay.
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patient treatment cost and the amount of cost saving generated
by CTC, especially for colorectal cancer with Dukes’ C and Dukes’
D. If we could include the costs of recurrence and metastasis, the
ICER would improve more.
Limitations and Future Research
In this study, we constructed the model so that it worked
adversely on introducing CTC where data were ambiguous,
because colorectal cancer epidemiological data were not sufﬁ-
cient. It is desirable to perform a reanalysis with more data for the
sensitivity and speciﬁcity of FOBT and a breakdown of the
medical costs for each stage of the Dukes’ classiﬁcation.
However, we did not consider the adverse events that may
occur with OC or CTC. Because OC was conducted by certiﬁed
physicians who passed the training course in Japan, physicians in
the National Cancer Center in Japan commented that adverse
events such as perforation could be ignored in Japan. Also,
radiologists commented that adverse events with CTC could be
ignored because of small radiation exposure. Therefore, we
ignored this issue in this model. But we had to take into account
that the risk of adverse events with OC or CTC could not be zero.
And, because this model ignores these risks, we should not forget
this point when we use the result of this analysis. In any case, we
would include these factors in future analyses to avoid this issue.
Policy Consideration
Overall results were largely affected by the uptake of OC. Larger
OC uptake induced better ICER and vice versa because of the
number of those who took OC, and the number of people with
colorectal cancer detected would be increased with higher OC
uptake. OC uptake varied much from one region to another, or
34.1% to 75.0% [10]. Thus, we need to take regional OC uptake into
account when we consider implementing and/or promoting CTC
to a speciﬁc region.Conclusions
In our analysis, the cost-effectiveness of CTC for a colorectal
cancer screening program in the working age population in Japan
was as follows. The ICER was JPY 1,646,000 per QALY gained for
strategy 2 and strategy 3 was dominant against strategy 1, both of
which were well below the Japanese threshold (JPY 5–6 million
per QALY gained) [31].
These ICER values will be further improved with a longer time
horizon (i.e., 30 years) than used in the basic analysis. Therefore,
adding CTC into the current colorectal cancer screening program
for the working age population seems to be a cost-effective
option.
Source of ﬁnancial support: These ﬁndings are the result of the
work partially funded by the American Medical Devices and
Diagnostics Manufacturers’ Association (AMDD).
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